24010-80-8

Usage

Guanidine derivative

It is derived from the guanidine structure, which is a common organic compound containing a nitrogen atom bonded to two carbon atoms.

Cyano group

The compound contains a cyano group (CN), which is a carbon atom triple-bonded to a nitrogen atom, providing the molecule with a strong electron-withdrawing property.

Ethyl group

1-Cyano-2-ethylguanidine also contains an ethyl group (C2H5), which is a two-carbon chain with a hydrogen atom and a methyl group attached to the carbons.

Primary use as a catalyst

1-cyano-2-ethylguanidine is mainly used as a catalyst in various chemical reactions, particularly in the production of polymers and resins.

Pharmaceutical intermediate potential

1-Cyano-2-ethylguanidine is being studied for its potential use as a pharmaceutical intermediate, which could lead to the development of new drugs and medications.

Hazardous substance classification

It is classified as a hazardous substance due to its potential health risks, such as skin and eye irritation, and harmful effects if ingested or inhaled.

Safety precautions

Proper safety measures should be taken when working with 1-cyano-2-ethylguanidine, including wearing appropriate personal protective equipment (PPE) and handling the compound in a well-ventilated area.

Upstream product

• 557-66-4 ethanamine hydrochloride 
• 1934-75-4 sodium dicyanamide 
• 5848-25-9 N-cyano-N'-ethyl-S-methylisothiourea 

Downstream Products

• 403603-30-5 N-[6-chloro-4-(2-nitrophenyl)quinazolin-2-yl]-N'-ethylguanidinium p-toluenesulfonate 
• 106592-54-5 3,5-diethyl-2-imino-4,6-dioxo-5-phenyl-tetrahydro-pyrimidine-1-carbonitrile 

Relevant academic research and scientific papers

In Vitro and in Vivo Inhibition of the Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT by Amidinoureas

A newly validated target for tuberculosis treatment is phosphopantetheinyl transferase, an essential enzyme that plays a critical role in the biosynthesis of cellular lipids and virulence factors in Mycobacterium tuberculosis. The structure-activity relat

DUAL INHIBITOR COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND ALZHEIMER'S DISEASE

The present invention relates to Compounds of Formula (I) and pharmaceutical compositions containing the same. It further relates to their use in the prevention or treatment of central nervous system diseases or disorders, in particular, cognitive, neurodegenerative or neuronal diseases or disorders.

Multitarget drug discovery for Alzheimer's disease: Triazinones as BACE-1 and GSK-3β inhibitors

Cumulative evidence strongly supports that the amyloid and tau hypotheses are not mutually exclusive, but concomitantly contribute to neurodegeneration in Alzheimer's disease (AD). Thus, the development of multitarget drugs which are involved in both pathways might represent a promising therapeutic strategy. Accordingly, reported here in is the discovery of 6-amino-4-phenyl-3, 4-dihydro-1, 3, 5-triazin-2(1H)-ones as the first class of molecules able to simultaneously modulate BACE-1 and GSK-3β. Notably, one triazinone showed well-balanced in vitro potencies against the two enzymes (IC50 of (18.03 ±0.01) μM and (14.67±0.78)μUM for BACE-1 and GSK-3β, respectively). In cell-based assays, it displayed effective neuroprotective and neurogenic activities and no neurotoxicity. It also showed good brain permeability in a preliminary pharmacokinetic assessment in mice. Overall, triazinones might represent a promising starting point towards high quality lead compounds with an AD-modifying potential.

3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3β Fragment Hits against Alzheimer's Disease

One of the main obstacles toward the discovery of effective anti-Alzheimer drugs is the multifactorial nature of its etiopathology. Therefore, the use of multitarget-directed ligands has emerged as particularly suitable. Such ligands, able to modulate different neurodegenerative pathways, for example, amyloid and tau cascades, as well as cognitive and neurogenic functions, are fostered to come. In this respect, we report herein on the first class of BACE-1/GSK-3β dual inhibitors based on a 3,4-dihydro-1,3,5-triazin-2(1H)-one skeleton, whose hit compound 1 showed interesting properties in a preliminary investigation. Notably, compound 2, endowed with well-balanced potencies against the two isolated enzymes (IC50 of 16 and 7 μM against BACE-1 and GSK-3β, respectively), displayed effective neuroprotective and neurogenic activities and no neurotoxicity in cell-based assays. It also showed good brain permeability in a pharmacokinetic assessment in mice. Overall, triazinone derivatives, thanks to the simultaneous modulation of multiple points of the diseased network, might emerge as suitable candidates to be tested in in vivo Alzheimer's disease models.

Synthesis of novel 4,6-di(substituted)amino- 1,2-dihydro-1,3,5-triazine derivatives as topical antiseptic agents

A series of novel 4,6-di(substituted)arnino-1,2-dihydro-1,3,5- triazine derivatives designed to have ClogP of 5.1-7.5 was synthesized and evaluated for their antiseptic properties by MIC and MBC tests against Gram-positive and Gram-negative bacteria, incl